for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Tyme Technologies Inc

TYME.OQ

Latest Trade

1.73USD

Change

-0.04(-2.26%)

Volume

588,327

Today's Range

1.66

 - 

1.79

52 Week Range

0.92

 - 

4.63

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.77
Open
1.79
Volume
588,327
3M AVG Volume
18.91
Today's High
1.79
Today's Low
1.66
52 Week High
4.63
52 Week Low
0.92
Shares Out (MIL)
111.95
Market Cap (MIL)
198.15
Forward P/E
-5.59
Dividend (Yield %)
--

Latest Developments

More

Tyme Reports Q1 Adjusted Loss Per Share $0.04

Tyme Announces Abstracts Selected For Presentation At The AACR Special Conference On Pancreatic Cancer

Tyme Announces Updated Data From A Mid-stage Study In Patients With Advanced Pancreatic Cancer

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Tyme Technologies Inc

Tyme Technologies, Inc. is a clinical-stage biotechnology company. The Company is focused on developing cancer therapeutics that is intended to be broadly effective across tumor types and have low toxicity profiles. The Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system. The Company’s lead clinical program, SM-88, is a first-in-class combination therapy in Phase II development for prostate cancer, and it is preparing to initiate an additional Phase II clinical trial for pancreatic cancer. The Company provides a novel compound for physicians to use in a treatment regimen for patients fighting six major cancers including breast, lung, prostate, gastric, esophageal and pancreatic cancers.

Industry

Biotechnology & Drugs

Contact Info

17 State St Fl 7

+1.212.4612315

https://www.tymeinc.com/

Key Stats

1.67 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2018

-0.210

2019

-0.310

2020(E)

-0.317
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
16.53
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
1.63
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-147.24
Return on Equity (TTM)
-124.81

Latest News

BRIEF-Tyme Technologies prices offering of 9 mln shares at $2.25 a share

* TYME TECHNOLOGIES ANNOUNCES PRICING OF ITS OFFERING OF 9 MILLION SHARES OF COMMON STOCK

BRIEF-Tyme Technologies Appoints Tommy Thompson To Board Of Directors

* TYME TECHNOLOGIES APPOINTS TOMMY G. THOMPSON TO BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-Tyme Technologies Says To Report Full Phase II Data For SM-88 In Second Half Of 2018

* TYME TECHNOLOGIES INC SAYS LOOK FORWARD TO REPORTING FULL PHASE II DATA FOR SM-88 IN SECOND HALF OF 2018 Source text for Eikon: Further company coverage:

BRIEF-Tyme Provides Clinical And Corporate Update For Fiscal Q3 2017

* TYME PROVIDES CLINICAL AND CORPORATE UPDATE FOR FISCAL THIRD QUARTER 2017

BRIEF-Tyme Provides Update On At-The-Market Financing Activity

* TYME TECHNOLOGIES INC - HAS RAISED GROSS PROCEEDS OF APPROXIMATELY $5.0 MILLION FROM ITS AT-THE-MARKET FINANCING FACILITY Source text for Eikon: Further company coverage:

BRIEF-Tyme reports encouraging efficacy and safety data from first human study of sm-88

* Tyme announces encouraging efficacy and safety data from first human study of sm-88 in women with metastatic breast cancer

BRIEF-Tyme Technologies files for mixed shelf offering of up to $250 mln

* Tyme Technologies Inc files for mixed shelf offering of up to $250 million - SEC filing Source text: [http://bit.ly/2eYTiIr] Further company coverage:

BRIEF-Tyme Briggs Morrison to advisory board

* Tyme adds distinguished drug developer, Briggs W. Morrison, M.D. to advisory board Source text for Eikon: Further company coverage:

BRIEF-Tyme Technologies files for non-timely 10-Q

* Tyme Technologies Inc files for non-timely 10-Q - SEC filing Source text: (http://bit.ly/2wv0vaL) Further company coverage:

BRIEF-TYME Technologies inc files for mixed shelf of upto $250 million - SEC Filing

* TYME Technologies Inc files for mixed shelf of upto $250 million - SEC Filing Source text: (http://bit.ly/2wri6R1) Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up